17-Alpha-Hydroxyprogesterone Caproate in Pregnant Women With Placenta Previa

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

Purpose to evaluate the effects of intramuscular 17-Alpha-Hydroxyprogesterone Caproate (17-OHPC) for prevention of Emergent Cesarean Delivery in symptomatic Pregnant Women with Placenta Previa

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aswan University Hospital
• Treatments: 11-hydroxyprogesterone; 17-alpha-hydroxy-progesterone caproate

Criteria

Inclusion Criteria:

• Estimated gestational age: between 24 weeks and 37 week's gestation

• Confirmed Placenta previa; either major or minor degrees.

• Placenta previa with preterm uterine contractions or with a history of at least single attack of mild vaginal bleeding

Exclusion Criteria:

• Severe attack of bleeding requiring an immediate intervention.

• Fetal heart rates instability or non-reassuring tracing

• Intrauterine fetal death or major fetal anomalies.

• If associated with abruptio placentae

• Patients with known bleeding disorders or on anticoagulant therapy

• Patients with severe medical disorders